Germany-based medical technology company Zeiss Medical Technology has secured the US Food and Drug Administration (FDA) 510(k) approval for its Intrabeam 700 platform.
Intrabeam 700 is an advanced robotic-assisted system that provides precision to enhance intraoperative radiation therapy (IORT).
Its digital-first architecture facilitates Smart workflow efficiency and seamless connectivity, benefiting patients with neuro-oncology and breast cancer.
The system’s advanced design, including the Zeiss Intrabeam Smart Stand, ensures precise applicator positioning by allowing rapid yet controlled movement within the cavity.
The design feature minimises residual vibrations, enhancing treatment accuracy.
Zeiss Medical Technology neuro- and spine surgery business sector head Christian Schwedes said: “Based on our established Intrabeam platform, the newly developed Zeiss Intrabeam 700 marks the next major step on our path to shaping the oncology workflows of tomorrow.
“It is especially designed for a precise, structured and risk-adapted treatment of brain tumours. The Zeiss Intrabeam 700 will support the efficient and seamless collaboration between neurosurgery and oncological therapy.”
The Intrabeam 700 platform features sterile Zeiss Intrabeam Smart Spherical Applicators with digital-assisted management, eliminating the need for sterilisation.
Its intuitive graphical user interface (GUI) simplifies operation, drawing from familiar Zeiss device interfaces.
The platform’s redesigned Radiance treatment planning software allows oncologists to simulate intraoperative radiation dosage parameters based on individual patient data.
It reduces unexpected treatment disruptions, optimising surgical oncology outcomes.
Intrabeam 700 integrates seamlessly with hospital systems, supports faster routine workflows and simplifies data management through direct access to digital solutions.
Furthermore, it includes integrated applicator recognition and confirmation via embedded Radio Frequency Identification (RFID) technology.
West Virginia University neurosurgeon Christopher Cifarelli said: “The new incarnation of the Intrabeam 700 really gives you more range of motion in the delivery of the applicator to the cavity. It gives you precision in how movements can be made inside of the resection cavity by the applicator.”
